Statement: both groups in the primary clinical trial are subjected to the same treatments, the difference lies in the kinds of cancer that the patients have.
Primary_evidence: INTERVENTION 1:    Nivolumab + Daratumumab (TNBC)   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) INTERVENTION 2:    Nivolumab + Daratumumab (NSCLC)   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)